

GUAM CANNABIS RULES & REGS

PREVENTING UNDERAGE MISUSE

Public Law 35-5

Underage cannabis use can harm cognitive development, lead to mental health issues, negatively impact academic performance, and increase the risk of addiction. Socially, it can strain relationships.

The purpose of PL 35-5 and its penalties is to highlight the importance of education and prevention.

WHAT YOU CAN DO

As a Parent/Caregiver:

You set the tone. You play a critical role in leading by example, limiting access to cannabis underage misuse, creating your family norms, and setting cannabis-related expectations.

As an adult 21 yrs and older:

Our youth are impressionable. Be their role model by refusing to provide or make any cannabis available to anyone under 21 yrs old, regardless of their relationship to you or the occasion.

PENALTIES

PL35-5 Subsection 70.44.4 & 70.53 – A, B, C, and D

Any person under twenty-one (21) years of age possessing cannabis shall be guilty of a petty misdemeanor and subject to:

- First Offense :
 - \$100.00 fine
 - Suspension of their driver's license for 12 months
- Each Subsequent Offense will be:
 - Subject to a \$250.00 fine
 - An additional 12 months suspension
 - Suspension of one's driver's license may be waived by the court and replaced with 100 hours of community service for each possession

A person twenty-one (21) years or older will be considered in violation if they:

- shall knowingly give or otherwise make available any alcoholic beverage or cannabis to a person under the age of 21 years.
- owns, occupies, or controls premises on which alcoholic beverages or cannabis are consumed by any person under 21 years of age and who knows of alcohol or cannabis consumption by persons under 21 years of age on such premises
- and, who could reasonably have prohibited or prevented such alcohol or cannabis consumption
- Any person in violation:
 - Shall be punished by a fine of not more than \$2,000 or by imprisonment for not more than 1 year or both

SCAN FOR
RESOURCES



The program supplies were developed under a grant from the Office of National Drug Control Policy (ONDCP) DFC Support Program, the US Department of Health and Human Services (HHS), and the Centers for Disease Control and Prevention (CDC). The views, policies, and opinions expressed are those of the authors and do not necessarily reflect those of the ONDCP, HHS, or CDC.